Details of the Drug Formulations

General Information of Drug (ID: DMV05SW)

• Drug Name: AS-1670542 Drug Info
• Synonyms: AVATROMBOPAG; 570406-98-3; AKR-501; UNII-3H8GSZ4SQL; 3H8GSZ4SQL; AKR 501; Avatrombopag [USAN:INN]; Doptelet; AS 1670542; Avatrombopag (USAN/INN); GTPL9953; DTXSID30205667; ZINC72190218; AKOS027323962; CS-3397; HY-13463; FT-0728753; D10306; AS1670542

Indication

Disease Entry	ICD 11	Status	REF
Thrombocytopenia	3B64	Approved	[1]
Idiopathic thrombocytopenic purpura	3B64.10	Phase 3	[2]

• Cross-matching ID:
  PubChem CID: 9852519
  CAS Number: 570406-98-3
  TTD ID: D0W1DI
  ACDINA ID: D00852

Full List of Drug Formulations Containing This Drug

Avatrombopag 20 mg tablet

Company	Formulation ID	FDA Description
Akarx	F23076	Lactose Monohydrate; Colloidal Silicon Dioxide; Crospovidone; Magnesium Stearate; Microcrystalline Cellulose; Polyvinyl Alcohol; Talc; Polyethylene Glycol; Titanium Dioxide; Ferric Oxide Yellow

References

• [1] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [2] ClinicalTrials.gov (NCT01433978) A Phase 3, Multicenter, Randomized, Double-blind, Active-controlled, Parallel-group Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Oral E5501 Versus Eltrombopag, in Adults With Chronic Immune Thrombocytopenia (Idiopathic Thrombocytopenic Purpura). U.S. National Institutes of Health.